We serve Chemical Name:sbb057044 CAS:67989-97-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:sbb057044
CAS.NO:67989-97-3
Synonyms:Dicyclopentyloxyethyl acrylate
Molecular Formula:C15H20O3
Molecular Weight:248.31700
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:321.8ºC at 760 mmHg
Density:N/A
Index of Refraction:
PSA:35.53000
Exact Mass:248.14100
LogP:2.33290
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like Dicyclopentyloxyethyl acrylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Dicyclopentyloxyethyl acrylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Dicyclopentyloxyethyl acrylate Use and application,Dicyclopentyloxyethyl acrylate technical grade,usp/ep/jp grade.
Related News: Lilly spokesperson Kathryn Beiser and a Justice Department spokesperson declined to comment. Clark did not respond to a request for comment. A Covington spokesperson did not respond to a request for comment nor to a request for a copy of the firm’s report. sbb057044 manufacturer Saudi Arabia��s state airline and Oman also suspended flights to China on Sunday in reaction to the coronavirus epidemic, according to Reuters. sbb057044 supplier Last year, California became the first state in the country to ban toxic chemicals in cosmetics — including a number of PFAS. Maryland did the same this month, but the laws don’t take effect until 2025, the Post reported. sbb057044 vendor INSPIRE is a global, multi-center, randomized, controlled study to assess the efficacy and safety of IV rigosertib in higher-risk MDS (HR-MDS) patients who had progressed on, failed to respond to, or relapsed after previous treatment with a hypomethylating agent (HMA) within nine cycles over the course of one year after initiation of HMA treatment. sbb057044 factory Lilly spokesperson Kathryn Beiser and a Justice Department spokesperson declined to comment. Clark did not respond to a request for comment. A Covington spokesperson did not respond to a request for comment nor to a request for a copy of the firm’s report.
